Corbus Pharmaceuticals (CRBP) Stock Analysis

What Corbus Pharmaceuticals does

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Key metrics

ETFs linked to CRBP

Broad-market and Healthcare sector ETFs an investor holding Corbus Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CRBP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Corbus Pharmaceuticals?

Corbus Pharmaceuticals trades under the ticker CRBP on NASDAQ.

Which exchange is CRBP listed on?

CRBP is listed on NASDAQ.

What sector does Corbus Pharmaceuticals operate in?

Corbus Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CRBP in a portfolio?

PortView shows CRBP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.